


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A compound according to Formula (1):



(1)

wherein:

Y represents $-C(O)-$ or a covalent bond;

R represents a substituted arylene, a substituted heteroarylene or a covalent bond;

Z represents $-CH_2-$, $-NR_3-$, $-O-$, $-C(O)NR_3-$, $-NR_3C(O)-$ or $-CH=CH-$ when R is a substituted arylene or a substituted heteroarylene, and represents $-CH_2-$ or $-CH=CH-$ when R is a covalent bond; R3 is hydrogen, C₁₋₃ substituted alkyl, and (CH₂)₀₋₂ -C₃₋₆ substituted carbocycle;

R1 is selected from the group consisting of:


hydrogen, C₁₋₃ substituted alkyl, C₂₋₃ substituted alkenyl, C₂₋₃ substituted alkynyl, and (CH₂)₀₋₂ -C₃₋₆ substituted carbocycle;

m is equal to 0 when Z = $-NR_3-$ or $-CH_2-$; or m is equal to 0 or 1 when Z = $-O-$, $-C(O)NR_3-$ or $-NR_3C(O)-$; or m is an integer between 0 and 6 when Z = $-CH=CH-$;

n is an integer equal to or greater than 2, appropriately chosen so that the number of atoms in the macrocyclic ring ranges from 13 to 16;

or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.

2. (Currently amended) [[A]] The compound according to claim 1, wherein R1 represents hydrogen; or a pharmaceutically acceptable salt thereof.
3. (Currently amended) [[A]] The compound according to claim 2, with the following absolute configuration:



or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.

4. (Currently amended). [[A]] The compound according to claim 3 selected from the group consisting of:
 - N-{[(5R)-16-(Dimethylamino)-4-oxo-2,3,15,17,18-pentaazabicyclo[12.3.1]octadeca-1(18),14,16-trien-5-yl]methyl}-N-hydroxyformamide;
 - N-{[(5R)-16-(4-Morpholinyl)-4-oxo-2,3,15,17,18-pentaazabicyclo[12.3.1]octadeca-1(18),14,16-trien-5-yl]methyl}-N-hydroxyformamide;
 - N-{[(5R)-16-(Cyclopropylamino)-4-oxo-2,3,15,17,18-pentaazabicyclo[12.3.1]octadeca-1(18),14,16-trien-5-yl]methyl}-N-hydroxyformamide;
 - N-{[(5R)-16-(4-Morpholinyl)-4-oxo-2,3,17,18-tetraazabicyclo[12.3.1]octadeca-1(18),14,16-trien-5-yl]methyl}-N-hydroxyformamide;
 - N-{[(5R)-16-Methyl-4-oxo-2,3,17,18-tetraazabicyclo[12.3.1]octadeca-1(18),14,16-trien-5-yl]methyl}-N-hydroxyformamide;
 - N-{[(5R)-4-Oxo-2,3,16,17-tetraazabicyclo[11.3.1]heptadeca-1(17),13,15-trien-5-yl]methyl}-N-hydroxyformamide;
 - N-{[(5R)-15-Methyl-4-oxo-2,3,16,17-tetraazabicyclo[11.3.1]heptadeca-1(17),13,15-trien-5-yl]methyl}-N-hydroxyformamide;

N-{{[(5R)-15-(4-Morpholinyl)-4-oxo-2,3,16,17-tetraazabicyclo[11.3.1]heptadeca-1(17),13,15-trien-5-yl]methyl}-N-hydroxyformamide;
 N-{{[(5R)-15-(2-Furanyl)-4-oxo-2,3,16,17-tetraazabicyclo[11.3.1]heptadeca-1(17),13,15-trien-5-yl]methyl}-N-hydroxyformamide;
 N-{{[(5R)-15-(4-Morpholinyl)-4-oxo-2,3,14,16,17-pentaazabicyclo[11.3.1]heptadeca-1(17),13,15-trien-5-yl]methyl}-N-hydroxyformamide;
 N-{{[(5R)-15-(Dimethylamino)-4-oxo-2,3,14,16,17-pentaazabicyclo[11.3.1]heptadeca-1(17),13,15-trien-5-yl]methyl}-N-hydroxyformamide;
 N-{{[(5R)-4-Oxo-2,3,15,16-tetraazabicyclo[10.3.1]hexadeca-1(16),12,14-trien-5-yl]methyl}-N-hydroxyformamide;
 N-{{[(5R)-14-Methyl-4-oxo-2,3,15,16-tetraazabicyclo[10.3.1]hexadeca-1(16),12,14-trien-5-yl]methyl}-N-hydroxyformamide;
 N-{{[(5R)-14-(Dimethylamino)-4-oxo-2,3,15,16-tetraazabicyclo[10.3.1]hexadeca-1(16),12,14-trien-5-yl]methyl}-N-hydroxyformamide;
 N-{{[(5R)-14-(4-Morpholinyl)-4-oxo-2,3,15,16-tetraazabicyclo[10.3.1]hexadeca-1(16),12,14-trien-5-yl]methyl}-N-hydroxyformamide; and
 N-{{[(4R)-3,15-Dioxo-1,2-diazacyclopentadecan-4-yl]methyl}-N-hydroxyformamide; or a pharmaceutically acceptable salt thereof.

5. (Canceled).
6. (New) The compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein Y represents $-C(O)-$.
7. (New) The compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein Y represents a covalent bond.
8. (New) The compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein R represents a covalent bond.

9. (New) The compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein R represents heteroarylene.
10. (New) The compound according to claim 10, or a pharmaceutically acceptable salt thereof, wherein R represents 1,3,5-triazinyl; 1,3,5-triazinyl substituted with one dimethylamino, morpholinyl, or cyclopropylamino; 2-pyrimidinyl; or 2-pyrimidinyl substituted with one methyl, dimethylamino, or morpholinyl.
11. (New) The compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein Z represents $-\text{CH}_2-$; and m is equal to 0.
12. (New) The compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein n is 5, 6, 7, or 9.
13. (New) The compound according to claim 3 wherein
Y represents $-\text{C}(\text{O})-$ or a covalent bond;
R represents 1,3,5-triazinyl; 1,3,5-triazinyl substituted with one dimethylamino, morpholinyl, or cyclopropylamino; 2-pyrimidinyl; or 2-pyrimidinyl substituted with one methyl, dimethylamino, or morpholinyl; or a covalent bond;
Z represents $-\text{CH}_2-$;
m is equal to 0; and
n is 5, 6, 7; or 9; or a pharmaceutically acceptable salt thereof.
14. (New) A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable carrier.